trending Market Intelligence /marketintelligence/en/news-insights/trending/SCAG7NFlpnAq_6r3u976vg2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

EMA accepts The Medicines Co.'s application for urinary tract infection drug

Blog

Needham & Company is Now Available in the S&P Global Market Intelligence Aftermarket Research Collection

Blog

Banking Essentials Newsletter - February Edition

Blog

Message in a (Word)Cloud

Six trends shaping the industries and sectors we cover in 2021


EMA accepts The Medicines Co.'s application for urinary tract infection drug

The European Medicines Agency acknowledged receipt of The Medicines Company's application for Vabomere to treat complicated urinary tract infections.

The application is backed by data from phase 3 trial. Vabomere was previously known as Carbavance.